Ravi Vij

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety

Ashraf Badros, Ravi Vij, Thomas Martin et al. · Leukemia · 2013 · 147 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16

The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma

Josh N. Vo, Yi‐Mi Wu, Jeanmarie Mishler et al. · Nature Communications · 2022 · 91 citations · Full text

Medicine, Molecular Genetics, Oncology +16

Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time

Shaji Kumar, Angela Dispenzieri, Raphael Fraser et al. · Leukemia · 2017 · 89 citations

Medicine, Hematology, Oncology +16

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Sikander Ailawadhi, Bertrand Arnulf, Krina K. Patel et al. · Blood · 2024 · 63 citations · Full text

Medicine, Oncology, Immunotherapy +13

Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation

H. Jean Khoury, Kathryn Trinkaus, M-J Zhang et al. · Biology of Blood and Marrow Transplantation · 2003 · 27 citations · Full text

Pharmacy, Immunology, Pharmacology +17